Nephros Inc: Form 10-K for the period ended Dec 31, 2025
Filed with the SEC on Mar 12, 2026 and accepted by EDGAR at Mar 12, 2026, 20:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $18.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $7.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $11.6m | us-gaap:GrossProfit |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2025-01-01 to 2025-12-31 | $9.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | $1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-01-01 to 2025-12-31 | $1.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $12.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | $1.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | $0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | $0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 10,968,063 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | $1.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-12-31 | $5.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $11.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $13.6m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $2.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $3.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $10.2m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001493152-26-009848. Last ingested by Listed: Oct 24, 2026, 15:10 ET. Listed shows no prices and gives no investment advice.